Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
Public ClinicalTrials.gov record NCT01794663. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
Study identification
- NCT ID
- NCT01794663
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Opsona Therapeutics Ltd.
- Industry
- Enrollment
- 252 participants
Conditions and interventions
Conditions
Interventions
- OPN-305 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2012
- Primary completion
- Jun 29, 2016
- Completion
- Jun 29, 2016
- Last update posted
- Feb 15, 2017
2012 – 2016
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Los Angeles | California | 90033 | — |
| Research Site | Washington D.C. | District of Columbia | 20007 | — |
| Research Site | Tampa | Florida | 33606 | — |
| Research Site | Chicago | Illinois | 60612 | — |
| Research Site | New Orleans | Louisiana | 70112 | — |
| Research Site | New Orleans | Louisiana | 70121 | — |
| Research Site | Livingston | New Jersey | 07039 | — |
| Research Site | New York | New York | 10065 | — |
| Research Site | The Bronx | New York | 10467 | — |
| Research Site | Harrisburg | Pennsylvania | 17105 | — |
| Research Site | Charleston | South Carolina | 29425 | — |
| Research Site | Dallas | Texas | 75246 | — |
| Research Site | Fort Worth | Texas | 76104 | — |
| Research Site | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01794663, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 15, 2017 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01794663 live on ClinicalTrials.gov.